Coronavirus

A major genetic risk factor for COVID-19, inherited from Neandertals, significantly reduces the risk of contracting HIV.

Due to decreased efficacy against the Omicron variant, the FDA is now recommending approved populations receive a higher dose of Evusheld (tixagevimab and cilgavimab) for COVID-19 prevention.

New research points to vaccine effectiveness against infection dropping from 68% to 12% in this pediatric population within a month.

A pair of studies released last weekend found the COVID-19 pandemic was caused by at least 2 zoonotic transmission events at the Huanan Seafood Wholesale Market in Wuhan, China.

Although it is possible, a small Danish study showed the majority of these cases were often mild and in unvaccinated individuals.

The waning of protection after full vaccination matters more than the advent of the more transmissible Delta variant in subjects who tested positive for COVID-19.

This is broken down into counties that are either high, medium, or low level categories. Many areas of the US are able to go without masks.

Among fully vaccinated people, being older than 60 years and having kidney failure were the only consistent predictors of severe COVID-19 disease and death.

The federal agency is going to lay out recommendations for states.

This is the first authorized COVID-19 vaccine that was developed by a Canadian-based company, and the first that used a plant-based protein technology.

CDC expands recommended timeline between second and third COVID-19 vaccine to 8 weeks for people 12 years and older, especially for young men, to reduce the risk of myocarditis.

Infection-acquired immunity to SARS-CoV-2 remains higher for longer when followed by vaccination.

The companies plan to seek regulatory authorization for the vaccine both in the US and Europe.

The IDSA, HIVMA, and SHEA released a statement opposing legal intervention on behalf of ivermectin as a COVID-19 treatment.

A clinician offers his perspective on how the virus is behaving and the role that vaccines and therapies will play.

COVID-19 patients’ ZIP codes influenced how sick they were upon hospitalization, and how much care they needed after admittance.

An Israeli study found COVID-19 reinfection was "relatively rare," and previously infected persons who also received at least 1 dose of the Pfizer-BioNTech mRNA vaccine had an 82% reduced risk of reinfection.

Study highlights elevated levels of antibody response in those with history of COVID-19.

COVID-19 mRNA vaccine effectiveness wanes even faster during Omicron than during Delta variant predominance, but a booster dose still provides lasting defense against COVID-19 hospitalization and death.

A study of patients at high risk of severe COVID-19 disease progression found ivermectin was no more effective than standard care at preventing adverse outcomes.

A preprint study shows the variant is resistant to some monoclonal antibodies and vaccines.

Regular symptom screening revealed completely asymptomatic COVID-19 infection is highly unlikely among unvaccinated people.

As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.

For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.

After presenting at CROI 2022, Dr. Jessica Justman discusses her community-level survey findings: COVID-19 infections do not vary by age.

Investigators looked at full vaccination and booster dose observational data to offer some insights on protection and breakthrough infections.

The idea of a future with COVID-19 is settling in, and building strategies that improve quality of life as we live with this viral disease are paramount.

Data shown in the Pinetree clinical trial and being presented with 2 posters at CROI demonstrate both benefits and safety in preventing progression to more severe disease.

In a study of people living with HIV in Taiwan, COVID-19 vaccination was highly effective when implemented alongside non-pharmaceutical interventions.

A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.